

# GBS Colonisation: Management of Infant to Prevent Early Onset Group B Streptococcus (EOGBS) Disease



## Key Points

- Intrapartum antibiotic prophylaxis reduces, but does not eliminate, EOGBS disease
- More than 90% of newborns with EOGBS disease develop clinical signs of sepsis within 24 hours of birth
- All newborns  $\geq$  35 weeks gestation must be assessed with the first set of observations after birth with the Neonatal Early-Onset Risk Calculator (NEORC, <https://neonatalsepsiscalculator.kaiserpermanente.org>) with ongoing clinical assessment to identify signs of EOS to continue after the initial risk calculation
- Antibiotics must be administered urgently, aiming for commencement within one hour of the decision to treat suspected sepsis being made.

## 1. Purpose

Early-onset neonatal Group B Streptococcus (EOGBS) disease is acquired by vertical transmission from a colonised mother, sometimes antenatally, but more frequently intrapartum when GBS either ascends from the vagina into the amniotic fluid or the infant is colonised during the birth process [1].

The past two decades have seen significant reductions in EOGBS infections following the widespread adoption of intrapartum antibiotic prophylaxis (IAP) as a means of interrupting vertical GBS transmission from mothers to their infants [2]. However, despite these reductions GBS disease remains a leading cause of neonatal morbidity and mortality in Australia and many other developed regions of the world [3-5].

IAP has altered the profile of newborn infants who develop EOGBS disease. Many affected infants lack the typical intrapartum risk-factors for GBS infection, are born to mothers with a negative GBS screen or represent missed opportunities for prevention. Clinicians should remain alert for signs of sepsis in any newborn infant.

This guideline outlines strategies for the identification and management of infants at risk of Group B Streptococcus infection at the Women's. This guideline accords with the 2010 Centers for Disease Control guideline [4].

## 2. Definitions

**GBS** (*Streptococcus agalactiae*) is a Gram positive bacteria that commonly colonizes the female genital tract (10-40% of pregnant women), may be transmitted to the infant intrapartum and is a common cause of early-onset neonatal infection [1].

**Intrapartum antibiotic prophylaxis (IAP)** is administration of antibiotic during labour with the intention of preventing GBS transmission from mother to infant.

**Early onset sepsis (EOS)** is defined by surveillance networks in Australia and New Zealand as infection in the first 48-hours of life [6, 7].

## 3. Responsibilities

**Obstetric and neonatal doctors** are responsible for identifying infants at risk of neonatal GBS disease, based upon antepartum or postpartum risk factors (e.g. inadequate GBS IAP in a colonized mother, an infant with clinical signs of sepsis).

**Midwives and Nurses** working on the maternity wards are responsible for identifying babies at potential risk of sepsis, based upon abnormal routine observations (heart rate, respiratory rate, temperature).

# GBS Colonisation: Management of Infant to Prevent Early Onset Group B Streptococcus (EOGBS) Disease



## 4. Guideline

### 4.1 Identifying infants at risk of GBS disease

IAP reduces, but does not eliminate, EOGBS disease [4]. Clinicians must therefore remain vigilant for signs of EOGBS infection. They should be aware that early-onset disease can occur in infants of culture-screened GBS negative women. Reports from countries where 'universal screening' based IAP is practiced record that up to 60% of EOGBS disease is in newborn infants whose mothers had a negative GBS screen [8].

Any newborn infant with signs of sepsis (eg. any combination of respiratory distress, apnoea, pallor with poor peripheral perfusion, fever  $\geq 38^{\circ}\text{C}$  or unstable temperature, and acidosis) should have a full diagnostic evaluation (usually full blood examination, blood culture, and chest x-ray if indicated) and receive benzylpenicillin and gentamicin (or consider benzylpenicillin and cefotaxime in some instances, [Sepsis in the Neonate – Identification, Evaluation and Management guideline](#), whilst awaiting the results of cultures [4, 9]. It is worth emphasising that clinical signs are highly sensitive indicators of sepsis [10].

Maternal chorioamnionitis indicates a high-risk for early-onset neonatal GBS disease, even when the mother has received appropriate intrapartum antibiotics [10].

In contrast, infants of GBS positive mothers who have received adequate IAP can be considered for discharge home within 24-hours of delivery, provided they can still be observed closely by an experienced health professional [9]. Several studies show that maternal IAP do not change the timing or clinical presentation of EOGBS disease with more than 90% of infants developing signs of sepsis within 24-hours of birth [10, 11].

### 4.2 Newborn assessment after birth

Refer to [Sepsis in the Neonate – Identification, Evaluation and Management guideline](#).

The [Neonatal Early-Onset Risk Calculator](#) (NEORC, <https://neonatalesepsiscalculator.kaiserpermanente.org>) must be performed with the first set of observations in all newborns  $\geq 35$  weeks gestation. [12]

Ongoing clinical assessment to identify signs of EOS should continue after the initial risk calculation.

## 5. Evaluation, monitoring and reporting of compliance to this guideline

Compliance to this guideline will be monitored by incidences reported to VHIMs and evaluated by annual review of episodes of Early Onset Group B Streptococcus Disease at The Women's.

## 6. References

- 1) Baker, C.J. and F.F. Barrett, Transmission of group B streptococci among parturient women and their neonates. *J Pediatr*, 1973. **83**(6): p. 919-25.
- 2) Garland, S.M. and J.R. Fliegner, Group B streptococcus (GBS) and neonatal infections: the case for intrapartum chemoprophylaxis. *Aust N Z J Obstet Gynaecol*, 1991. **31**(2): p. 119-22.
- 3) Daley, A.J. and D. Isaacs, Ten-year study on the effect of intrapartum antibiotic prophylaxis on early onset group B streptococcal and Escherichia coli neonatal sepsis in Australasia. *Pediatr Infect Dis J*, 2004. **23**(7): p. 630-4.
- 4) Verani, J.R., L. McGee, and S.J. Schrag, Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. *MMWR Recomm Rep*. **59**(RR-10): p. 1-36.
- 5) Clifford, V., S.M. Garland, and K. Grimwood, Prevention of neonatal group B streptococcus disease in the 21st century. *J Paediatr Child Health*, 2011.
- 6) Daley, A.J. and S.M. Garland, Prevention of neonatal group B streptococcal disease: progress, challenges and dilemmas. *J Paediatr Child Health*, 2004. **40**(12): p. 664-8.

# GBS Colonisation: Management of Infant to Prevent Early Onset Group B Streptococcus (EOGBS) Disease



the women's  
the royal women's hospital

- 7) Grimwood, K., et al., Early-onset neonatal group B streptococcal infections in New Zealand 1998-1999. *J Paediatr Child Health*, 2002. **38**(3): p. 272-7.
- 8) Van Dyke, M.K., et al., Evaluation of universal antenatal screening for group B streptococcus. *N Engl J Med*, 2009. **360**(25): p. 2626-36.
- 9) Campbell, N., et al., The prevention of early-onset neonatal group B streptococcus infection: technical report from the New Zealand GBS Consensus Working Party. *N Z Med J*, 2004. **117**(1200): p. U1023.
- 10) Escobar, G.J., et al., Neonatal sepsis workups in infants  $\geq$ 2000 grams at birth: A population-based study. *Pediatrics*, 2000. **106**(2 Pt 1): p. 256-63.
- 11) Bromberger, P., et al., The influence of intrapartum antibiotics on the clinical spectrum of early-onset group B streptococcal infection in term infants. *Pediatrics*, 2000. **106**(2 Pt 1): p. 244-50.
- 12) Kuzniewicz MW, Puopolo KM, Fischer A, Walsh EM, et al. A Quantitative, risk-based approach to the management of neonatal early-onset sepsis. *JAMA Pediatrics* 2017;171:365.

## 7. Legislation/Regulations related to this guideline

Not Applicable.

## 8. Appendices

Not Applicable.

Please ensure that you adhere to the below disclaimer:

### PGP Disclaimer Statement

The Royal Women's Hospital Clinical Guidelines present statements of 'Best Practice' based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women's this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.

Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated

In view of the possibility of human error and / or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.

You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner.

NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.